From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
|Videos|March 10, 2022
Amblyopia management: A new paradigm
Author(s)Robert Sanet, OD, Brooke Henson, Editor
Robert Sanet, OD, explains the new paradigm in amblyopia, or lazy eye, management
Advertisement
During SECO 2022, Robert Sanet, OD, co-director of Sanet Vegara Vision Seminar, based in San Diego, discussed the SECO 2022 lecture he’s presenting along with Pilar Vergara, OD titled “A new paradigm for amblyopia management”.
Advertisement
Related to this article
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
Kwaku Osei, OD, PhD, FAAO, discussed patient-reported outcomes with a senofilcon C (Johnson & Johnson; Acuvue Vita), reusable lens, with the majority of wearers rating comfort, vision, and handling favorably.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
2
Takeaways from this week in optometry: October 16-23
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
More than monitoring: Using AMD visits to promote healthy vision aging
5